Search
COPD Clinical Trials in Chattanooga, TN
A listing of 3 COPD clinical trials in Chattanooga, TN actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 3 of 3
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
COPD
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Chattanooga, Tennessee, currently has 3 active clinical trials seeking participants for COPD research studies.
Featured Trial
Studying an Investigational Treatment for Adults with Chronic Obstructive Pulmonary Disease (COPD)
Recruiting
This Phase 3 study aims to evaluate the impact of an approved COPD treatment compared to an investigational treatment on lung function in adults aged 40 to 80 years old with COPD. Participants will attend in-clinic study visits approximately weekly during the screening period. Afterward, visits will occur every 4 weeks to administer take-home study treatment, perform lung function tests, and assess overall health and safety. Should you express interest, you will be contacted directly by the research site, who will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Chronic obstructive pulmonary disease (COPD)
All Conditions
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Respiratory Syncytial Virus (RSV) Treatment Study
Recruiting
We’re seeking volunteers to participate in a RSV treatment study.
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Conditions:
RSV
Respiratory Syncytial Virus (RSV)
Healthy
Healthy Volunteers
Healthy Subjects
Featured Trial
Respiratory Syncytial Virus (RSV) Treatment Study
Recruiting
We’re seeking volunteers to participate in a RSV treatment study.
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Conditions:
RSV
Respiratory Syncytial Virus (RSV)
Healthy
Healthy Volunteers
Healthy Subjects
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
04/03/2025
Locations: ClinSearch, LLC, Chattanooga, Tennessee
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Impairments That Affect Correct Inhaler Use in COPD
Recruiting
INHALE is a one-year, multi-site observational research study funded by Viatris, with two aims:
1. Determine the prevalence of both cognitive impairment and impaired manual dexterity in stable out-patients with chronic obstructive pulmonary disease (COPD).
2. Assess the relationship of cognitive impairment and impaired manual dexterity with patient errors using current pMDIs, SMIs and/or DPIs.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
11/15/2024
Locations: Erlanger Health, Chattanooga, Tennessee
Conditions: COPD
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/23/2024
Locations: Research Site, Chattanooga, Tennessee
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
1 - 3 of 3